Here's What Key Metrics Tell Us About AtriCure (ATRC) Q4 Earnings

Zacks Zacks
Here's What Key Metrics Tell Us About AtriCure (ATRC) Q4 Earnings

AtriCure (ATRC) reported $140.5 million in revenue for the quarter ended December 2025, representing a year-over-year increase of 13.1%. EPS of $0.06 for the same period compares to -$0.08 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $140.49 million, representing a surprise of +0.01%. The company delivered an EPS surprise of +400%, with the consensus EPS estimate being -$0.02.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how AtriCure performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: United States Revenue- Pain management: $22.65 million versus the three-analyst average estimate of $21.64 million. The reported number represents a year-over-year change of +27.3%. International Revenue- Pain management: $1.79 million compared to the $2.55 million average estimate based on three analysts. The reported number represents a change of -3.6% year over year. United States Revenue- Total: $114.33 million versus $113.62 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +12.6% change. International Revenue- Total: $26.17 million compared to the $26.53 million average estimate based on three analysts. The reported number represents a change of +15.3% year over year. United States Revenue- Total ablation ( Open ablation+Minimally invasive ablation+Pain management): $68.86 million versus the three-analyst average estimate of $66.62 million. The reported number represents a year-over-year change of +12.4%. International Revenue- Minimally invasive ablation: $2.12 million compared to the $2.68 million average estimate based on three analysts. The reported number represents a change of -16.5% year over year. United States Revenue- Appendage management: $45.48 million versus the three-analyst average estimate of $47.01 million. The reported number represents a year-over-year change of +12.8%. International Revenue- Appendage management: $11.41 million compared to the $10.86 million average estimate based on three analysts. The reported number represents a change of +22.9% year over year. United States Revenue- Open ablation: $38.48 million versus $37.29 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +16.7% change. International Revenue- Open ablation: $10.84 million compared to the $10.44 million average estimate based on three analysts. The reported number represents a change of +20.3% year over year. United States Revenue- Minimally invasive ablation: $7.73 million compared to the $7.68 million average estimate based on three analysts. The reported number represents a change of -26.2% year over year. International Revenue- Total ablation ( Open ablation+Minimally invasive ablation+Pain management): $14.76 million versus the three-analyst average estimate of $15.67 million. The reported number represents a year-over-year change of +10%.

View all Key Company Metrics for AtriCure here>>>

Shares of AtriCure have returned -16.4% over the past month versus the Zacks S&P 500 composite's -1.4% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.

Beyond Nvidia: AI's Second Wave Is Here

The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. Little-known AI firms tackling the world's biggest problems may be more lucrative in the coming months and years.

See

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
AtriCure, Inc. (ATRC): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

Outras notícias